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Abstract Because canine mammary tumours constitute a
serious clinical problem and there are no good prognos-
tic markers (only histopathological variables are used),
the aim of the presented study was to find new malig-
nancy markers as well as to identify intracellular path-
ways and biological processes characteristic for canine
mammary malignancy. We compared gene expression of
the most malignant mammary tumours (poorly differen-
tiated cancers of the 3rd grade of malignancy) with less
malignant tumours (well differentiated cancers of the 1st
grade of malignancy). The results of our study indicated
that in dogs the number of tumour-infiltrating myeloid
cells or expression of myeloid-specific antigens by can-
cer cells is related to the cancer progression and may
constitute a new marker of malignancy, however further stud-
ies in this field are required.
Keywords Caninemammary cancer .Malignancymarkers .
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Introduction
Spontaneous mammary tumours are the most prevalent type
of malignant neoplasm in the bitch and woman with the three
times over incidence in dog (MacEwen 1990). About 50 % of
all the mammary tumours are malignant (Misdorp 2002). The
aetiology of mammary cancer is very complex and not clearly
understood. The known mediators of tumourigenesis in both
species are: genetic, hormonal, dietary, environmental and
carcinogenic factors (Russo and Russo 1998). Moreover, both
species live in the same conditions, thus the dog is a good
model for breast cancer studies.
The role of oestrogens, progestins and growth hormone in
canine mammary cancer development has been documented
(Pawłowski et al. 2012). That is why mainly affected are not
spayed female dogs in the middle age. The early ovariectomy
reduces risk of mammary cancer development (Misdorp
1991). However, the high morbidity and mortality rate, which
is caused by poor diagnostics and ineffective treatment strat-
egies makes this problem still actual in both humans and dogs.
The conventional approach to cancer therapy provide treat-
ment according to the organ in which the cancer originates.
However, different intracellular signalling pathways are
perturbed in the various cancers even if they represent the
same type. Thus, the patients with the same type of cancer
often have dissimilar genetic defects in their tumours and
respond in a heterogeneous manner to anticancer agents
(Veer van’t and Bernards 2008). Moreover, the diagnostic
methodologies available in veterinary oncology may still be
considered to be in progress. So far, only histopathological
variables (tumour size, lymph node status, vascular invasion
and tumour grade of differentiation) are used as prognostic
parameters (Manuali et al. 2012).
Thus, the aim of the presented study was to find intracellular
pathways and biological processes characteristic for canine
mammary malignancy. We compared gene expression of the
most malignant mammary tumours (poorly differentiated
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cancers of the 3rd grade of malignancy) with less malignant
tumours (well differentiated cancers of the 1st grade of malig-
nancy) in order to find new diagnostic and prognostic markers.
Materials and methods
Tissue samples
Tumour samples of canine mammary cancers were
obtained from patients subjected to surgery. The tumours
then, were divided into two equal halves, one of them
was fixed in 10 % neutral buffered formalin and routine-
ly embedded in paraffin to perform histological assay.
The other was snap frozen in liquid nitrogen and stored
in −80 °C. Four μm samples from paraffin blocks were
fixed on glass slides, stained with haematoxylin—eosin
(HE) and examined by certified pathologists (prof. Dr.
hab. Elżbieta Malicka and Dr. Izabella Dolka, both from
the Warsaw University of Life Sciences, Poland). The
immunohistochemical examination of cytokeratin,
vimentin, smooth muscle actin, s100 protein and p63
Table 1 Primers sequences used in this study and their annealing
optimal temperature and time. The mRNA sequences of key genes
were obtained from NCBI database. Primers were designed using
PRIMER3 software (free on-line access) and checked using Oligo
Calculator (free on-line access) and Primer-Blast (NCBI database).
Rps19 gene was used as a non-regulated reference gene for normali-
zation of target gene expression (Brinkhof et al. 2006; Etschmann et al.
2006)




il15 CAGACTCACCGAAGAGGAAA CTGCTGTGAAGTCTGGGAGT 60 6
ergic2 TGCCATCGTCTGCTACATTA CAGTCGCCTCTCACTCTCAT 61 9
elspb1 CTTTCACATCACTGCACTCG GTGTGTTGGGAGGTGAGTTC 60 6
extl3 AGCTTGCTGGTGAAAAGGAC TTATAGTCAAGGGCATATCC 60 6
rps19 CCTTCCTCAAAAAGTCTGGG GTTCTCATCGTAGGGAGCAAG 61 10
Fig. 1 Gene Spring (Agilent,
USA) diagrams of: a. boxplots
showing median relative signal
measured for each microarray;
b. quality control gene
expression in both microarray
experiments (in dye-swaps)
shows highly repeatable results;
c. all genes expression in both
microarray experiments
(in dye-swaps), genes that
differed significantly
at p value <0.01 with fold
cut-off = 1.5 (unpaired t-test
and Benjamin-Hochberg
FDR<5 % correction) are
showed as blue points
(they were taken to the
further analyses)
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Table 2 The list of up-regulated genes (↑) in canine mammary cancers of the 3rd grade of malignancy compared with the canine mammary cancers
of the 1st grade of malignancy. Data was analyzed using Gene Spring software (Agilent, USA), p<0.005, Fold change >3
Fold Change Gene symbol Description
1 ↑5.0125217 IL8 Canis lupus familiaris interleukin 8 (IL8), mRNA [NM_001003200]
2 ↑4.714284 FABP1 Fatty acid binding protein Fragment [Source:UniProtKB/TrEMBL;Acc:Q95KW5]
[ENSCAFT00000011880]
3 ↑4.2913084 MMP1 Matrix metalloproteinase 1
4 ↑4.2044907 EXTL3 Exostosin-like 3;EXTL3;ortholog
5 ↑3.957821 CNGA1 Canis lupus familiaris cyclic nucleotide gated channel alpha 1 (CNGA1), mRNA
[NM_001003222]
6 ↑3.925793 NELL2 PREDICTED: Canis familiaris similar to Protein kinase C-binding protein NELL2
precursor (NEL-like protein 2) (Nel-related protein 2), transcript variant 2 (LOC477636),
mRNA [XM_846523]
7 ↑3.9208682 CNGA1 Canis lupus familiaris cyclic nucleotide gated channel alpha 1 (CNGA1), mRNA
[NM_001003222]
8 ↑3.416843 MMP3 Canis lupus familiaris matrix metallopeptidase 3 (stromelysin 1, progelatinase)
(MMP3), mRNA [NM_001002967]
9 ↑3.2882302 NELL2 NEL-like 2 (chicken) [Source:HGNC Symbol;Acc:7751] [ENSCAFT00000015264]
10 ↑3.0424755 MTMR10 PREDICTED: Canis familiaris similar to phosphatidylinositol-3-phosphatase associated
protein, transcript variant 4 (LOC479016), mRNA [XM_851476]
11 ↑2.972987 ADCY8 adenylate cyclase 8 (brain) [Source:HGNC Symbol;Acc:239] [ENSCAFT00000001672]
12 ↑2.596691 MARCO macrophage receptor with collagenous structure [Source:HGNC Symbol;Acc:6895]
[ENSCAFT00000007902]
13 ↑2.486832 EMR3 Canis lupus familiaris egf-like module containing, mucin-like, hormone receptor-like
3 (EMR3), mRNA [NM_001038666]
14 ↑2.31884 IL6 Canis lupus familiaris interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_001003301]
15 ↑2.2737932 SRGN PREDICTED: Canis familiaris similar to Secretory granule proteoglycan core protein
precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoetic
proteoglycan core protein) (Serglycin) (LOC609421), mRNA [XM_846674]
16 ↑2.1735125 ELSPBP1 Epididymal sperm-binding protein 1;ELSPBP1;ortholog
17 ↑2.1602907 LEF1 PREDICTED: Canis familiaris similar to lymphoid enhancer binding factor-1, transcript
variant 7 (LOC478507), mRNA [XM_858241]
18 ↑2.1465235 GAD1 Canis lupus familiaris glutamate decarboxylase 1 (brain, 67 kDa) (GAD1), mRNA
[NM_001097543]
19 ↑2.0999904 CTRB1 PREDICTED: Canis familiaris similar to chymotrypsinogen B1, transcript variant
1 (LOC479650), mRNA [XM_536782]
20 ↑2.0861115 IL15 Interleukin-15;IL15;ortholog
21 ↑2.001695 DDIT3 DNA-damage-inducible transcript 3 [Source:HGNC Symbol;Acc:2726] [ENSCAFT00000000367]
22 ↑1.975823 PCSK2 proprotein convertase subtilisin/kexin type 2 [Source:HGNC Symbol;Acc:8744]
[ENSCAFT00000008876]
23 ↑1.9757178 GPM6A PREDICTED: Canis familiaris similar to glycoprotein M6A isoform 1, transcript variant
6 (LOC475641)
24 ↑1.9687057 HLA-DQB1 Canis lupus familiaris major histocompatibility complex, class II, DQ beta 1
(HLA-DQB1), mRNA [NM_001014381]
25 ↑1.9438797 SLC30A8 solute carrier family 30 (zinc transporter), member 8 [Source:HGNC Symbol;Acc:20303]
[ENSCAFT00000001287]
26 ↑1.9432139 LYZL6 Q6UW30_HUMAN (Q6UW30) TKAL754, partial (63 %) [TC51642]
27 ↑1.8990102 CDA cytidine deaminase [Source:HGNC Symbol;Acc:1712] [ENSCAFT00000023893]
28 ↑1.8836564 NELL1 PREDICTED: Canis familiaris similar to nel-like 1 precursor (LOC476888),
mRNA [XM_534090]
29 ↑1.8206882 CELA1 Canis lupus familiaris chymotrypsin-like elastase family, member 1 (CELA1),
mRNA [NM_001003007]
30 ↑1.8029478 CAMP Canis lupus familiaris cathelicidin antimicrobial peptide (CAMP), mRNA [NM_001003359]
31 ↑1.7610306 ERGIC2 Endoplasmic reticulum-Golgi intermediate compartment protein 2;ERGIC2;ortholog
32 ↑1.7566903 PRKCQ protein kinase C, theta [Source:HGNC Symbol;Acc:9410] [ENSCAFT00000008336]
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protein expression was performed (data not shown). The
tumour types of specimens were classified based on
the World Health Organization (WHO) Histological
Classification and Mammary Tumours of the Dog and
Cat classification (Misdorp et al. 1999). Histological
tumour grading was conducted on HE-stained sections
using a Misdorp classification (2002). The mammary
carcinoma grading was assessed in respect to tubule
formation, degree of differentiation and mitotic index as. All
the tumours examined were classified as the 1st grade of
malignancy or the 3rd grade of malignancy (6 tumours in
each group). Unfortunately survival data of these dogs is
unavailable.
Microarray analyses
The total RNA from the samples was isolated using a
Total RNA kit (A&A Biotechnology, Poland) according
to the manufacturer’s protocol. Isolated RNA samples
were dissolved in RNase-free water. The quantity of
RNA was measured using NanoDrop (NanoDrop
Technologies USA). The samples with adequate amounts
of RNA were treated with DNaseI to eliminate a possi-
bility of DNA contamination. The samples were subse-
quently purified using RNeasy MiniElute Cleanup Kit
(Qiagen, Germany). Finally RNA samples were analyzed
using BioAnalyzer (Agilent, USA) to measure the final
RNA quality and integrity.
The Quick Amp Labeling Kit (Agilent, USA) was
used to amplify and label target RNA to generate com-
plementary RNA (cRNA) for oligo microarrays used in
gene expression profiling and other downstream analy-
ses. The gene expression of the poorly differentiated,
most malignant tumours was compared against the gene
expression of the well differentiated tumours (the 1st
grade of malignancy). Samples were examined in four
repetitions (two dye-swaps to eliminate the effect of
label factor). Thus, each biological condition was la-
belled once by Cy3 and once by Cy5. Taking the
average of all labelled arrays, the dye effect on any
particular gene was cancelled. The hybridization was
performed with canine-specific AMADID Release GE
4x44K microarrays (Agilent, USA) using Gene Expression
Hybridization Kit (Agilent, USA) according to the manufac-
turer’s protocol.
Signal detection, quantification and analysis
Acquisition and analysis of hybridization intensities
were performed using DNA microarray scanner
(Agilent, USA). Then, the results were extracted using
Agilent’s Feature Extraction Software with normaliza-
tion and robust statistical analyses. Results were ana-
lyzed for statistical purposes using Future Extraction
and Gene Spring software (Agilent, USA). The unpaired
t-test with Benjamin-Hochberg FDR<5 % (false discov-
ery rate) correction was applied (with p value cut-off <0.01).
For further analysis we chose only these genes with values
within upper and lower cut-off (100.00 and 20.00, respective-
ly) in each of the slide, whose expression changed at least 1.5-
fold in each of examined slide. The area of the analyses
covered in this publication has been deposited in NCBI’s
Gene Expression Omnibus and is accessible via GEO Series
accession number GSE 44033.
Gene function was identified using the PANTHER
pathway analysis software (Mi et al. 2005) and
Pathway Studio software (Agilent, USA). PANTHER on-
line platform allowed for wide analysis of the Canis
familiaris regulated genes and also for statistical analy-
sis of number of regulated genes involved in specific
pathways or biological functions compared to the normal
healthy cell of this specie.
Real-time qPCR
The mRNA sequences of the key genes were obtained from
NCBI database. Primers were designed using PRIMER3
software (free on-line access) and checked using Oligo
Table 2 (continued)
Fold Change Gene symbol Description
33 ↑1.7566395 TFPI2 tissue factor pathway inhibitor 2 [Source:HGNC Symbol;Acc:11761] [ENSCAFT00000023103]
34 ↑1.7506666 LAMP3 lysosomal-associated membrane protein 3 [Source:HGNC Symbol;Acc:14582]
[ENSCAFT00000018703]
35 ↑1.725342 S100P S100 calcium binding protein P [Source:HGNC Symbol;Acc:10504] [ENSCAFT00000022770]
36 ↑1.7065927 TREM1 triggering receptor expressed on myeloid cells 1 [Source:HGNC Symbol;Acc:17760]
[ENSCAFT00000002493]
37 ↑1.6830823 BCL2A1 BCL2-related protein A1 [Source:HGNC Symbol;Acc:991] [ENSCAFT00000022179]
38 ↑1.6449332 IL33 Canis lupus familiaris interleukin 33 (IL33), mRNA [NM_001003180]
39 ↑1.597691 AREGB amphiregulin B
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Table 3 The list of down-regulated genes (↓) in canine mammary cancers of the 3rd grade of malignancy compared with the canine mammary
cancers of the 1st grade of malignancy. Data was analyzed using Gene Spring software (Agilent, USA), p<0.005, Fold change >1.5
Fold Change Gene Symbol Description
1 ↓1.5897567 SMOC1 SPARC related modular calcium binding 1 [Source:HGNC Symbol;Acc:20318] [ENSCAFT00000026288]
2 ↓1.6253631 SERPINE1 Canis lupus familiaris serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1),
member 1 (SERPINE1), mRNA [NM_001197095]
3 ↓1.6317778 GDPD2 glycerophosphodiester phosphodiesterase domain containing 2 [Source:HGNC Symbol;Acc:25974]
[ENSCAFT00000026677]
4 ↓1.6928551 TTC17 tetratricopeptide repeat domain 17 [Source:HGNC Symbol;Acc:25596]
[ENSCAFT00000010834]
5 ↓1.7700043 PIP prolactin-induced protein [Source:HGNC Symbol;Acc:8993] [ENSCAFT00000005869]
6 ↓1.9344714 PPP2R2B PREDICTED: Canis familiaris similar to protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52),
beta isoform isoform 1, transcript variant 1 (LOC478053), mRNA [XM_535231]
7 ↓1.9801016 ACAN Canis lupus familiaris aggrecan (ACAN), mRNA [NM_001113455]
8 ↓2.0213842 BMP7 Bone morphogenetic protein 7 Fragment (BMP-7)(Osteogenic protein 1)(OP-1)
[Source:UniProtKB/Swiss-Prot;Acc:P34819] [ENSCAFT00000019076]
9 ↓2.0953069 PPP6R3 PREDICTED: Canis familiaris similar to sporulation-induced transcript 4-associated
protein, transcript variant 7 (LOC483688), mRNA [XM_858601]
10 ↓2.2811608 NOTUM notum pectinacetylesterase homolog (Drosophila) [Source:HGNC Symbol;Acc:27106]
[ENSCAFT00000009543]
11 ↓2.3086379 PRSS16 protease, serine, 16 (thymus) [Source:HGNC Symbol;Acc:9480] [ENSCAFT00000017667]
12 ↓2.3557005 LRP2 low density lipoprotein receptor-related protein 2 [Source:HGNC Symbol;Acc:6694]
[ENSCAFT00000019396]
13 ↓2.3743253 FMOD fibromodulin [Source:HGNC Symbol;Acc:3774] [ENSCAFT00000015038]
14 ↓2.3969395 FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) [Source:HGNC Symbol;
Acc:3557] [ENSCAFT00000017685]
15 ↓2.5347118 LALBA Canis lupus familiaris lactalbumin, alpha- (LALBA), mRNA [NM_001003129]
16 ↓2.630961 MYOC Canis lupus familiaris myocilin, trabecular meshwork inducible glucocorticoid
response (MYOC), mRNA [NM_001048030]
17 ↓2.7111955 LOX lysyl oxidase [Source:HGNC Symbol;Acc:6664] [ENSCAFT00000000805]
18 ↓2.7223504 SLC22A10 solute carrier family 22, member 10 [Source:HGNC Symbol;Acc:18057] [ENSCAFT00000024230]
19 ↓2.7353601 COL2A1 Canis lupus familiaris collagen, type II, alpha 1 (COL2A1), mRNA [NM_001006951]
20 ↓2.74712 ACSM4 acyl-CoA synthetase medium-chain family member 4 [Source:HGNC
Symbol;Acc:32016] [ENSCAFT00000028528]
21 ↓2.8774078 PAQR8 progestin and adipoQ receptor family member VIII [Source:HGNC Symbol;Acc:15708]
[ENSCAFT00000003464]
22 ↓3.2135046 MGAT4C mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme
C (putative) [Source:HGNC Symbol;Acc:30871] [ENSCAFT00000009653]
23 ↓3.331683 EPYC epiphycan [Source:HGNC Symbol;Acc:3053] [ENSCAFT00000009916]
24 ↓3.341357 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9
[Source:HGNC Symbol;Acc:15995] [ENSCAFT00000028000]
25 ↓3.625558 FXYD2 FXYD domain containing ion transport regulator 2 [Source:HGNC Symbol;Acc:4026]
[ENSCAFT00000020395]
26 ↓4.1011486 SCG2 PREDICTED: Canis familiaris similar to Secretogranin-2 precursor (Secretogranin II)
(SgII) (Chromogranin C), transcript variant 1 (LOC488550), mRNA [XM_545669]
27 ↓4.2103615 RIPPLY1 PREDICTED: Canis familiaris similar to Down syndrome critical region homolog 6 (LOC610288), mRNA
[XM_847751]
28 ↓4.6913886 TAF7L TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated factor,
50 kDa [Source:HGNC Symbol;Acc:11548] [ENSCAFT00000027954]
29 ↓5.1920776 MYH2 Canis lupus familiaris myosin, heavy chain 2, skeletal muscle, adult (MYH2),
mRNA [NM_001076795]
30 ↓5.9604554 MYH1 Canis lupus familiaris myosin, heavy chain 1, skeletal muscle, adult (MYH1),
mRNA [NM_001113717]
31 ↓7.348387 POU1F1 Canis lupus familiaris POU class 1 homeobox 1 (POU1F1), mRNA [NM_001006949]
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Calculator (free on-line access) and Primer-Blast (NCBI
database). Primers’ sequences are listed in Table 1. Rps19
gene was used as a non-regulated, reference gene for
normalization of target gene expression (Brinkhof et al.
2006; Etschmann et al. 2006). Quantitative RT-PCR was
performed using fluorogenic Lightcycler Fast Strand DNA
Sybr Green (Roche) and the Light Cycler (Roche). The
results were analyzed using comparative Ct method
(Schmittgen and Livak 2008). Relative transcript abun-
dance of the gene equals ΔCt values (ΔCt = Ctreference –
Cttarget). Relative gene expression is expressed as ΔΔCt
value (ΔΔCt=2 -ΔCt). The experiment was conducted in
triplicates.
Then, to visualize the PCR product it was dedicated for
electrophoresis in 2 % agarose gel (Sigma Aldrich), stained
with ethidium bromide (Sigma Aldrich) and run for 60 min
at 90 mV in 1× tris-borate-EDTA buffer. Then, the gel was
visualized under UV light.
Results
Gene expression in canine mammary malignancy
The microarray-based transcriptional profile of the canine
mammary cancers of the 3rd grade of malignancy was
Fig. 2 Classification of
up-regulated genes in canine
mammary cancers of the 3rd
grade of malignancy (a.) and in
canine mammary cancers of the
1st grade of malignancy (b.)
according to their involvement
in biological processes
(based on the PANTHER
Database, www.pantherdb.org)
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compared to the canine mammary cancers of the 1st grade of
malignancy used as a reference. For each comparison 2
separate dye-swap experiments were performed. This study
showed 70 statistically significant (p<0.005; Fold change =
1.5) regulated genes (Fig. 1). Further analysis showed 39
up-regulated genes (Table 2) and 31 down-regulated genes
(Table 3) in canine mammary cancer of the 3rd grade of
malignancy.
Function of identified genes
PANTHER analysis of identified up-regulated genes showed
that they were mainly involved in biological processes such
as: cellular process (NELL2, NELL1, CNGA1, PRKCQ,
S100P, EMR3, PCSK2, IL15, IL8, MARCO, IL6, CAMP,
GPM6A, BCL2A1), metabolic process (MMP3, LEF1,
ADCY8, CELA1, PRKCQ, LYZL6, TFPI2, S100P, MMP1,
PCSK2, MTMR10, CAMP, AMP3, EXTL3) and develop-
mental process (NELL2, NELL1, PRKCQ, EMR3, PCSK2,
IL8, GPM6A, BCL2A1) (Fig. 2a). The most significant path-
way in which up-regulated genes (n=12) were involved was
the inflammation mediated by chemokine and cytokine
signaling pathway (HLA-DQB1, NELL1, LYZL6,
S100P, TFPI2, TREM1, EMR3, IL6, IL8, IL15, MARCO,
CAMP). Analysis of the down-regulated genes showed
that they were involved mainly in metabolic process,
cellular process, cell communication and developmental
process (Fig. 2b). Pathway analysis showed that these
genes were mainly involved in cytoskeletal regulation
by Rho GTPase, GnRH receptor pathway, inflammation
mediated by chemokine and cytokine, nicotinic acetyl-
choline receptor signaling pathway and Wnt signaling
pathway.
Real-time qPCR gene expression
For the purpose of microarray data validation, we have ran-
domly selected 4 genes: il15, ergic2, elspb1 and extl3. Real-
time qPCR results showed similar trends in gene expression
changes as were observed in microarray studies (Fig. 3). The
expression of examined genes was higher in the most malig-
nant canine mammary cancers than in the tumours of the 1st
grade of malignancy.
Discussion
Canine mammary cancer constitutes a serious clinical
problem. That is a reason why its molecular biology
has been systematically examined during the last few years
(Rao et al. 2009; Pawłowski et al. 2011, Klopfleish et al. 2010;
Pawłowski et al. 2013).
The very interesting study was conducted by Klopfleisch
et al. (2010) who identified a gene expression profile in canine
mammary tumours that was associated with early metastatic
spread to the lymph nodes. Based on the gene expression
pattern of these tumours the authors were able to discriminate
carcinomas with divergent metastatic potential despite similar
histological features. Moreover, a partial overlap was found
between the canine mammary “metastatic” gene expression
profile and similar metastasis-associated gene expression
“signature” of breast cancer (Veer et al. 2002).
Our previous study of gene expression in canine mammary
tumours of various grade of malignancy showed that histo-
logical diagnosis was distinct from molecular diagnosis
(Pawłowski et al. 2013). We have also identified cellular
pathways and biological processes in which the most
Fig. 3 Results for agarose gel electrophoresis of examined gene’s PCR
products following real time Sybr green amplification (a.). The RT-
qPCR expression of examined genes (n=3) (b.). Estimated relative
gene expression for each gene was compared between canine
mammary carcinomas of the 3rd grade of malignancy and of the 1st
grade of malignancy (ANOVA and Tukey test; Graph Pad Prism 3.0,
USA). The p value <0.05 was regarded as significant and marked as *,
p<0.001 was regarded as highly significant and marked as **
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significant up-regulated genes were involved. In the tumours
of the 3rd grade of malignancy we identified interesting up-
regulated cluster of genes related to immunological system.
Their higher expression found in the most malignant cancers
might be related with increased recruitment of hematopoietic
cells into the tumour mass. Although the tumour is composed
of various cells depending on the tumour type, myeloid cells
seem to form a major component (Bingle et al. 2002). Clinical
studies have shown a correlation between the number of
myeloid cells (mainly macrophages) and a poor prognosis in
many human cancers (e.g. breast, prostate, ovarian, etc.)
(Jadus et al. 1996). Our own studies conducted on canine
mammary cancers have not shown any correlation between
number of macrophages in tumour mass and a grade of
tumour malignancy (Król et al. 2011). However, interestingly
we observed expression of myeloid cell antigens in cancer cell
lines and tissues (Król et al. 2011, 2012) which increased upon
the co-culture of these both types of cells (Król et al. 2012).
We have shown that expression of typical macrophage anti-
gens (CD14, CSF-1R) in canine mammary cancer tissues
correlated with the tumour grade of malignancy (Król et al.
2011). Similarly, Dr. Pollard (2008) described that a gene
expression signature characteristic for macrophages was an
independent predictor of poor outcome in follicular lympho-
ma. Thus, these genes were typed as new malignancy
markers.
Based on these results, the aim of the presented study was
two-fold: 1) to compare gene expression in canine mamma-
ry tumours of the 1st and the 3rd grade malignancy in order
to find new possible prognostic markers and 2) to validate
whether genes characteristic for immunological system can
constitute new markers of malignancy.
Similarly to our previous study (Pawłowski et al. 2013) we
showed significant over-manifestation of genes related with
chemokine and cytokine mediated signalling pathway (HLA-
DQB1, NELL1, LYZL6, S100P, TFPI2, TREM1, EMR3, IL6,
IL8, IL15, MARCO, CAMP) (Fig. 2, Tables 2 and 3). A few of
these genes seemed to be particularly interesting. For example,
S100P calcium binding protein (which expression is regulated
by androgens and IL6 – another up-regulated gene in the most
malignant canine mammary tumours) is though as a new
prognostic factor (Parkkila et al. 2008). A correlation was
found between its increased expression and poor survival,
cancer proliferation and increased resistance to chemotherapy
(Maciejczyk et al. 2013). Our results are in accordance with
clinical data as the cancers of high grade of malignancy (which
express higher levels of S100P) are associated with an
increased risk of death within 2 years after mastectomy
(Karayannopoulou et al. 2005).
In the most malignant canine mammary cancers an in-
creased expression of two metalloproteinases (MMPs): 1
and 3 was observed (Table 2). MMPs comprise a structurally
and functionally related family degrading extracellular matrix
and basement membrane barriers. That is why they are
thought to play a key role in angiogenesis, inflammatory
processes, cancer development and metastasis, as well as in
proliferation and apoptosis (Sauter et al. 2008). Because of
their role in the degradation of the extracellular matrix leading
to tumor invasion and metastasis, they may also serve as
prognostic markers (Pardo and Selman 2005, Brickerhoff
and Matrisian 2002). In this context, MMPs have been fo-
cused on as targets for therapeutic strategies.
The metalloproteinases are also linked to specific aspects
of an inflammatory or immune response, such as the gener-
ation of chemokine gradients or immune cell influx (Hojilla
et al. 2008). In addition to the metalloproteinase-mediated
generation of inflammation triggers, metalloproteinases are,
in turn, utilized by immune cells to further propagate the
inflammatory reaction. In breast cancer samples, MMPs are
found in neutrophils, macrophages, and T lymphocytes as
well as in cancer cells (Benaud et al. 1998).
Cancer development is a complex process. In addition to
the cancer cell intrinsic factors, the cancer microenviron-
ment composed of various cells influences the behavior of
cancer cells. The results of our study indicate that in dogs
the number of tumour-infiltrating myeloid cells or expres-
sion of myeloid-specific antigens by cancer cells is related
to the cancer progression and may constitute a new marker
of malignancy, however further studies in this field are
required.
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